Pharmaceutical formulation containing gelling agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
1. A solvent system comprising:
(a) a solvent; and
(b) a solute comprising:
(i) an opioid analgesic in an effective amount to provide an analgesic effect upon oral administration;
(ii) an emulsifier;
(iii) a fatty acid ester;
(iv) a cellulosic polymer; and
(v) silicon dioxide.
2. The solvent system of claim 1 , having a ratio of emulsifier to opioid analgesic from about 15:1 to about 1:1 by weight.
3. The solvent system of claim 2 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 1:1 by weight.
4. The solvent system of claim 2 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 2:1 by weight.
5. The solvent system of claim 2 , wherein the ratio of emulsifier to opioid analgesic is from about 8:1 to about 5:1 by weight.
6. The solvent system of claim 1 , wherein the cellulosic polymer is hydroxyethylcellulose.
7. The solvent system of claim 1 , further comprising cellulose acetate butyrate.
8. The solvent system of claim 1 , wherein the solvent system comprises triacetin.
9. The solvent system of claim 1 , further comprising a surfactant.
10. The solvent system of claim 1 , wherein the solvent system comprises triacetin and a surfactant.
11. The solvent system of claim 1 , wherein the opioid analgesic comprises oxycodone base.
12. The solvent system of claim 11 , comprising from about 2.5 mg to about 320 mg of oxycodone base.
13. The solvent system of claim 11 , comprising about 10 mg, about 20 mg, about 40 mg or about 80 mg oxycodone base.